Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy
2019 · Proceedings of the National Academy of Sciences · 93 citations
https://doi.org/10.1073/pnas.1911385116
S
Salvatore Lopez
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
198
Papers
3.8K
Citations
37
h-index
74
i10-index
Salvatore Lopez is an academic researcher from Universidad de Buenos Aires. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Ovarian cancer diagnosis and treatment & Endometrial and Cervical Cancer Treatments. The author has an h-index of 37, co-authored 169 publications.
ORCID: 0000-0001-7705-3715Papers by this author
worksPrevalence and role of HER2 mutations in cancer
2019 · Pharmacology & Therapeutics · 79 citations
https://doi.org/10.1016/j.pharmthera.2019.03.010
T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2
2014 · Clinical & Experimental Metastasis · 65 citations
https://doi.org/10.1007/s10585-014-9688-8
Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan
2020 · Scientific Reports · 59 citations
https://doi.org/10.1038/s41598-020-58009-3
Erratum: PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
2015 · British Journal of Cancer · 51 citations
https://doi.org/10.1038/bjc.2015.388
HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor
2013 · Gynecologic Oncology · 46 citations
https://doi.org/10.1016/j.ygyno.2013.08.033
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat